within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX10_Olaratumab;

model Olaratumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FX10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FX10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Olaratumab is a recombinant human IgG1 monoclonal antibody that targets platelet-derived growth factor receptor alpha (PDGFRα). It was developed for the treatment of advanced soft tissue sarcoma in combination with doxorubicin. The drug was granted accelerated approval by the FDA in 2016, but this approval was subsequently withdrawn after confirmatory trials failed to demonstrate a clinical benefit.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in adult patients with advanced solid tumors (including soft tissue sarcoma) after intravenous administration.</p><h4>References</h4><ol><li><p>Villalobos, VM, et al., &amp; Cronier, DM (2020). Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. <i>Cancer medicine</i> 9(3) 882–893. DOI:<a href=&quot;https://doi.org/10.1002/cam4.2728&quot;>10.1002/cam4.2728</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31821732/&quot;>https://pubmed.ncbi.nlm.nih.gov/31821732</a></p></li><li><p>Andrick, BJ, &amp; Gandhi, A (2017). Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma. <i>The Annals of pharmacotherapy</i> 51(12) 1090–1098. DOI:<a href=&quot;https://doi.org/10.1177/1060028017723935&quot;>10.1177/1060028017723935</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28778132/&quot;>https://pubmed.ncbi.nlm.nih.gov/28778132</a></p></li><li><p>Chiorean, EG, et al., &amp; Amato, R (2014). A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 73(3) 595–604. DOI:<a href=&quot;https://doi.org/10.1007/s00280-014-2389-9&quot;>10.1007/s00280-014-2389-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24452395/&quot;>https://pubmed.ncbi.nlm.nih.gov/24452395</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Olaratumab;
